1. Clofazimine pharmacokinetics in patients with TB: dosing implications. (3rd August 2020) Authors: Abdelwahab, Mahmoud Tareq; Wasserman, Sean; Brust, James C M; Gandhi, Neel R; Meintjes, Graeme; Everitt, Daniel; Diacon, Andreas; Dawson, Rodney; Wiesner, Lubbe; Svensson, Elin M; Maartens, Gary; Denti, Paolo Journal: Journal of antimicrobial chemotherapy Issue: Volume 75:Number 11(2020) Page Start: 3269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Issue 9979 (2nd May 2015) Authors: Dawson, Rodney; Diacon, Andreas H; Everitt, Daniel; van Niekerk, Christo; Donald, Peter R; Burger, Divan A; Schall, Robert; Spigelman, Melvin; Conradie, Almari; Eisenach, Kathleen; Venter, Amour; Ive, Prudence; Page-Shipp, Liesl; Variava, Ebrahim; Reither, Klaus; Ntinginya, Nyanda E; Pym, Alexand... Journal: Lancet Issue: Volume 385:Issue 9979(2015) Page Start: 1738 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers. Issue 6 (30th December 2020) Authors: Li, Mengchun; Saviolakis, George A.; El‐Amin, Wael; Makhene, Mamodikoe K.; Osborn, Blaire; Nedelman, Jerry; Yang, Tian J.; Everitt, Daniel Journal: Clinical pharmacology in drug development Issue: Volume 10:Issue 6(2021) Page Start: 634 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗